Antagonizing IL-6 in ankylosing spondylitis: A short review

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 4, 2012, Pages 262-265

  Rajalingham, Sakthiswary ^a   Das, Srijit ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Ankylosing spondylitis; Inflammation; Interleukin 10; Interleukin 6; Pathogenesis; Treatment; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SARILUMAB; SILTUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; JUVENILE RHEUMATOID ARTHRITIS; NEUTROPENIA; OSTEOCLASTOGENESIS; RECOMMENDED DRUG DOSE; REVIEW; SPONDYLOARTHROPATHY;

ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN-6; SPONDYLITIS, ANKYLOSING;

EID: 84869823545     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812800958979     Document Type: Review

References (31)

1. Gyurcsik, Z.N.; András, A.; Bodnár, N.; Szekanecz, Z.; Szántó, S. Improvement in pain intensity, spine stiffness, and mobility during a controlled individualized physiotherapy program in ankylosing spondylitis. Rheumatology, 2011 Dec 25 [Epub ahead of print].
2. Rudwaleit, M.; Braun, J.; Sieper, J. Assessment of Spondyloarthritis international society. ASAS classification criteria for axial spondyloarthritis. Z. Rheumatology, 2009, 68, 591-593.
3. Rojas-Vargas, M; Muñoz-Gomariz, E.; Escudero, A.; Font, P.; Zarco, P.; Almodovar, R.; Gratacós, J.; Mulero, J.; Juanola, X.; Montilla, C.; Moreno, E.; Collantes-Estevez, E.; Registro Español de Espondiloartritis de la Sociedad Española de Reumatología Working Group. First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatology (Oxford), 2009, 48, 404-409.
4. th ed; Elsevier Saunders: Philadelphia, 2005.
5. th ed.; Lippincott Williams and Wilkins: Philadelphia, 2005.
6. Souza, L.S.; Machado, S.H.; Brenol, C.V.; Brenol, J.C.; Xavier, R.M. Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis. J. Rheumatol., 2008, 35, 2265-2271.
7. Nishimoto, N.; Kishimoto, T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol, 2008, (181), 151-160.
8. Thompson C.A. FDA approves tocilizumab to treat rheumatoid arthritis. Am. J. Health Sys. Pharm., 2010, 67(4), 254.
9. Schafer, J.A.; Kjesbo, N.K.; Gleason, P.P. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J. Manag. Care Pharm., 2010, 16(6), 402-416.
10. Sikora, K.A.; Grom, A.A. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr. Opion. Paed., 2011, 23(6), 640-646.
11. Puchalski, T.; Prabhakar, U.; Jiao, Q.; Berns, B.; Davis, H.M. Pharmacokinetic and pharmacodynamic modeling of an anti- interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin. Cancer. Res., 2010, 16(5), 1652-1661.
12. Im, C.H.; Kang, E.H.; Ki, J.Y.; Shin, D.W.; Choi, H.J.; Chang, E.J.; Lee, E.Y.; Lee, Y.J.; Lee, E.B.; Kim, H.H.; Song, Y.W. Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. Clin. Exp. Rheumatol, 2009, 27(4), 620-625.
13. Hashizume, M.; Mihara, M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis, 2011, 2011, 765-624.
14. Protogerou, A.D.; Zampeli, E.; Fragiadaki, K.; Stamatelopoulos, K.; Papamichael, C.; Sfikakis, P.P. A pilot study of endothelial dysfunction and aortic stiffness after in terleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis, 2011, 219(2), 734-736.
15. Wendling, D.; Bossert, M.; Prati, C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine., 2010, 77, 624-625.
16. Shima Y.; Tomita, T.; Ishii, T.; Morishima, A.; Maeda, Y,; Ogata, A.; Kishimoto, T.; Tanaka, T. Tocilizumab, a humanized antiinterleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod. Rheumatol., 2011, DOI:10;1007/s10165-011-0416-9.
17. Brulhart, L.; Nissen, M.J.; Chevallier, P.; Gabay, C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone. Spine., 2010, 77, 625-626.
18. Henes, J.C.; Horger, M.; Guenaydin, I.; Kanz, L.; Koetter, I. Mixed response to tocilizumab for ankylosing spondylitis. Ann. Rheum. Dis, 2010, 69, 2217-2218.
19. Cohen, J.D.; Ferreira, R.; Jorgensen, C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J. Rheumatol., 2011, 38(7), 1527.
20. Tanaka, T.; Kuwahara, Y.; Shima, Y.; Hirano, T.; Kawai, M.; Ogawa, M.; Arimitsu, J.; Hagihara, K.; Narazaki, M.; Ogata, A.; Kawase, I.; Kishimoto, T. Successful treatment of reactive arthritiswith a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis. Rheum., 2009, 61,1762-1764.
21. Brulhart, L.; Nissen, M.J.; Chevallier, P.; Gabay, C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonist. Joint Bone Spine, 2010, 77, 616-627.
22. Ogata, A.; Umegaki, N.; Katayama, I.; Kumanogoh, A.; Tanaka, T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine, 2011, Sep 29, DOI: 10.1016/j.jbspin.2011.06.011.
23. Del Castillo Pinol, L.; Gossec, L.; Sparsa, L.; Roux, C.; Dougados, M. Tocilizumab for treatment of refractory spondyloarthritis: report of 5 patients. Ann. Rheum. Dis. Supl., EULAR 2011, THUO 0493.
24. Dudler J.: Aubry-Rozier, B. Tocilizumab in axial spondylarthropathies: about 18 cases. Ann. Rheum. Dis., 2011, 70, 128.
25. Zochling, J.; van der Heijde, D.; Burgos-Vargas, R.; Collantes, E.; Davis, J.C. Jr.; Dijkmans B.; ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis., 2006, 65(4), 442-452.
26. van der Heijde D.; Landewe, R.; Einstein, S.; Ory, P.; Vosse, D.; Ni, L.: Lin, S.L.; Tsuji, W.; Davis, J.C. Jr. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis. Rheum., 2008, 58(5), 1324-1331.
27. Poddubnyy, D.; Rudwaleit, M.; Haibel, H.; Listing, J.; Marker-Hermann, E.; Zeidler, H.; Braun, J.; Sieper, J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann. Rheum. Dis., 2011, 70(8), 1369-1374.
28. Nakahara H.; Song, J.: Sugimoto, M.; Hagihara, K.; Kishimoto, T.; Yoshizaki K.; Nishimoto, N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis. Rheum., 2003, 48(6), 1521-1529.
29. Dankbar, B.; Padro,́ T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R.M.; Serve, H.; Berdel, W.E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interac tions in multiple myeloma. Blood, 2000, 95, 2630-2636.
30. Ankylosing Spondylitis and Spondyloarthritides: Treatment: Targeting Interleukin 6. Medscape Today URL: http://www.medscape.com/ viewarticle/745234_4. last accessed on 9.1.2012.
31. Filiopoulos, V.; Vlassopoulos, D. Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes. Inflam. Allergy - Drug Targets, 2009, 8, 369-382.